Related Experiment Videos
Regulatory T-cells in type 1 diabetes
Amy E Juedes1, Matthias G von Herrath
1Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA, USA.
Diabetes/Metabolism Research and Reviews
|September 24, 2004
Summary
Type 1 diabetes involves T-cell destruction of pancreatic beta cells. Enhancing regulatory T-cells (Tregs), including CD4+CD25+ and CD4+ Th2-like Tregs, offers a targeted treatment approach for this autoimmune disease.
Area of Science:
- Immunology
- Endocrinology
- Autoimmune Diseases
Background:
- Type 1 diabetes is an autoimmune condition characterized by T-cell mediated destruction of pancreatic beta cells.
- Disease progression is linked to Th1-type cytokine-producing T-cells, complicating treatment without broad immunosuppression.
- Autoimmune diseases involve both autoaggressive and autoregulatory T-cell components.
Purpose of the Study:
- To review the potential of enhancing regulatory T-cell responses for treating type 1 diabetes.
- To focus on two key types of regulatory T-cells: CD4+CD25+ and CD4+ Th2-like regulatory T-cells.
Main Methods:
- This is a review article, synthesizing existing evidence on regulatory T-cells in type 1 diabetes.
- Focuses on naturally occurring (CD4+CD25+) and adaptive (CD4+ Th2-like) regulatory T-cells.
Main Results:
- Regulatory T-cells represent a promising therapeutic target for type 1 diabetes.
- Both naturally occurring and adaptive regulatory T-cells play crucial roles in immune homeostasis.
Conclusions:
- Enhancing regulatory T-cell responses is a key strategy for treating type 1 diabetes.
- Understanding CD4+CD25+ and CD4+ Th2-like regulatory T-cells is vital for developing effective immunotherapies.